Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
This webinar will feature presentations from 3 speakers on the topic of Using Visualisations to Help Make Decisions.
The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.
In this webinar you will hear an introduction to what a patient preference study is as well as an overview of where this type of study can inform regulatory decision making. This will be followed by 2 examples looking at potential approaches to eliciting patient preference.
This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R. An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…
PSI Toxicology SIG workshop – 24th and 25th November 2020 The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another. This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types. The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee. The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow. The agenda and topics that will be discussed are yet to be finalised, but please get in touch with gareth.thomas@covance.com if you have suggestions. Full details will be circulated in the coming weeks.
GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.
GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.
GSK has a thriving global community of Oncology statisticians supporting our commitment to the development of new oncology therapies with the life-changing potential of helping patients with cancer. Click to learn about our exciting career opportunities.
We offer an interesting, diversified and challenging position, good contractual conditions, flexible working models, all the social benefits of a modern company and a professional environment where you will have the opportunity for personal growth.
We offer an interesting, diversified and challenging position, good contractual conditions, flexible working models, all the social benefits of a modern company and a professional environment where you will have the opportunity for personal growth.
Wish you were here? Recognised recently as a Top CRO by Life Science Leader, Premier Research is a medium sized, full service, global CRO with circa 1,500 employees worldwide, perfectly positioned to be big enough to help, yet small enough to care.
We currently have vacancies in our Early Phase and Late Phase Teams, for either home or office based positions across EMEA, so please reach out for more information.
Why not come and work for a company recognised as one of the UK's Top 25 Best Big Companies to Work For. The continued growth of our pipeline means we have opportunities for exceptional statisticians at all levels to join our Biostatistics group.
